The present invention relates to mutants of Fibroblast Growth Factor (FGF),particularly FGF-20 and FGF-2 1, which contain newly introduced N-linked or O-linked glycosylation site(s). The polynucleotide coding sequences for themutants, expression cassettes comprising the coding sequences, cellsexpressing the mutants, and methods for producing the mutants are alsodisclosed. Further disclosed are pharmaceutical compositions comprising themutants and method for using the mutants.